ANAVEX LIFE SCIENCES CORP. (AVXL)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$131.8M
Cash & Equivalents
$7.2M
Quarterly Burn Rate
55 mo
Est. Cash Runway
$232M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06245213 A Study of ANAVEX3-71 in Adults With Schizophrenia PHASE2 Active Not Recruiting 71

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AVXL.

SEC EDGAR Filings

All SEC filings for ANAVEX LIFE SCIENCES CORP. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.